4-(氯甲基)-2-(4-氟苯基)-1,3-唑 | 22091-39-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(氯甲基)-2-(4-氟苯基)-1,3-唑
• 英文名称: 4-Chloromethyl-2-(4-fluorophenyl)oxazole
• 英文别名: 4-(Chloromethyl)-2-(4-fluorophenyl)-1,3-oxazole
• CAS: 22091-39-0
• 化学式: C₁₀H₇ClFNO
• mdl: MFCD08276487
• 分子量: 211.623
• InChiKey: GVPZSTFLDSJXRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  4-(氯甲基)-2-(4-氟苯基)-1,3-唑 在 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.5h， 生成 2-(2-(4-fluorophenyl)oxazol-4-yl)acetonitrile
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS
  [FR] COMPOSÉS ET PROCÉDÉS

  摘要：

  揭示了具有以下公式的化合物：其中X1、X2、X3、R1、R2、R3、R4、Y、A、n和L的定义如本文所述，并且揭示了制备和使用这些化合物的方法。

  公开号：

  WO2011088187A1
• 作为产物：
  描述：

  对氟苯甲醛 在 lithium aluminium tetrahydride 、 氯化亚砜 、 potassium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基乙酰胺 为溶剂， 反应 26.0h， 生成 4-(氯甲基)-2-(4-氟苯基)-1,3-唑
  参考文献：
  名称：

  Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against MDR- and XDR-MTB

  摘要：

  A high-throughput screening effort on 45,000 compounds resulted in the discovery of a disubstituted oxazole as a new structural class inhibitor of Mycobacterium tuberculosis (Mtb). In order to improve the activity and investigate the SAR of this scaffold, a series of disubstituted azole analogues have been designed and synthesized. The newly synthesized compounds 1a-y were evaluated for their in vitro anti-TB activity versus replicating, multi-and extensive drug resistant Mtb strains. All the compounds, except 1o, 1p and 1q, showed potent anti-TB activity with MIC of 1-64 mg/L. The test of broad spectrum panel revealed that this series are specific to Mtb. The cytotoxicity assessment indicated that the compounds were not cytotoxic against HEK 293 cells. The compounds could have a novel mechanism to anti-Mtb as they can inhibit drug sensitive and drug resistant Mtb. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.09.072

文献信息

• ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION
  申请人：Zablocki Jeff

  公开号：US20080032995A1

  公开（公告）日：2008-02-07

  Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.

  揭示了具有以下结构的新型异黄酮衍生物，其可用作ALDH-2抑制剂，用于治疗哺乳动物对成瘾药物的依赖，例如对多巴胺类药物如可卡因、吗啡、安非他命、尼古丁和酒精的依赖。
• ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS
  申请人：Diamond Ivan

  公开号：US20090124672A1

  公开（公告）日：2009-05-14

  Disclosed are isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for use treating in mammals suffering from psychiatric disorders such as, for example, depression, generalized anxiety, social phobia, panic disorder, and sleep disorders.

  披露的是具有公式I结构的异黄酮衍生物，它们作为ALDH-2抑制剂，用于治疗遭受精神疾病困扰的哺乳动物，例如抑郁症、广泛性焦虑症、社交恐惧症、恐慌症和睡眠障碍。
• [EN] ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION<br/>[FR] INHIBITEURS D'ALDH-2 DANS LE TRAITEMENT D'UNE ACCOUTUMANCE
  申请人：CV THERAPEUTICS INC

  公开号：WO2009094028A1

  公开（公告）日：2009-07-30

  Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.

  揭示了具有Formula I结构的新型异黄酮衍生物，可用作ALDH-2抑制剂，用于治疗哺乳动物对成瘾药物的依赖，例如对多巴胺类药物如可卡因、吗啡、安非他命、尼古丁和酒精的依赖。
• Chemical Compounds
  申请人：Turnbull Philip Stewart

  公开号：US20090170907A1

  公开（公告）日：2009-07-02

  This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.

  这项发明涉及非甾体化合物，它们是雄激素、糖皮质激素、矿质皮质激素和孕激素受体的调节剂，以及这些化合物的制备和使用方法。
• Structural and Activity Relationships of 6-Sulfonyl-8-Nitrobenzothiazinones as Antitubercular Agents
  作者：Dongguang Fan、Bin Wang、Giovanni Stelitano、Karin Savková、Rui Shi、Stanislav Huszár、Quanquan Han、Katarína Mikušová、Laurent R. Chiarelli、Yu Lu、Chunhua Qiao

  DOI：10.1021/acs.jmedchem.1c01049

  日期：2021.10.14

  exploration introduced five-member aromatic heterocycles as linkers to attach an aryl group as the side chain. Our work led to the discovery of a number of BTZ derived compounds with potent antitubercular activity. The optimized compounds 6 and 38 exhibited MIC 47 and 30 nM, respectively. Compared to PBTZ169, both compounds displayed increased aqueous solubility and higher stability in human liver microsomes

  苯并噻嗪酮 (BTZ) 支架化合物 PBTZ169 通过抑制必需的黄素酶 DprE1 杀死结核分枝杆菌，从而阻断细胞壁成分阿拉伯聚糖的合成。虽然最小抑制浓度 (MIC) 低于 0.2 ng/mL，对结核分枝杆菌非常有效，但其低水溶性和生物利用度问题仍需解决。在这里，我们设计并合成了一系列6-甲磺酰基取代的BTZ类似物；进一步的探索引入了五元芳族杂环作为连接体以连接芳基作为侧链。我们的工作导致发现了许多具有强效抗结核活性的 BTZ 衍生化合物。优化的化合物6和38分别表现出 MIC 47 和 30 nM。与 PBTZ169 相比，这两种化合物在人肝微粒体中均表现出更高的水溶性和更高的稳定性。该研究表明，可以实施替代侧链修饰策略来改善基于 BTZ 的化合物的药物性质。